Tenax Therapeutics, Inc.
- TENX
- NASDAQ
- Biotechnology
- Cardiovascular/Pulmonary Drugs
- Levosimendan (TNX-103/102)
$1.52
Today +11.76%Quote Oct 19, 2026, 08:00 PM UTC
−26.88%over the last month
Max drawdown −31.3%From 1-month high −31.3%3 months −91.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
15
Founded
1967
Market value
$56.9M
Quote Oct 19
Floor
$1.31
13.8% below price
Resistance
$1.58
3.9% above price
Price vs analyst targets
9 analysts
Lowest target
$4.00Highest target
$5.00
$4.00Highest target
$5.00
- Price $1.52
- Average target $4.40
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 189% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TENXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free